Literature DB >> 1383113

The fenestrated Fontan procedure.

N D Bridges1, A R Castaneda.   

Abstract

In 90 patients with characteristics placing them at increased risk for a Fontan operation, a fenestration was created in the atrial baffle at the time of the Fontan repair. The rational was to allow a right to left shunt which would maintain cardiac output and limit right atrial pressure in the presence of conditions which limit pulmonary blood flow. Early mortality was 4/90 (4%), with an additional two patients having the Fontan repair taken down to a bidirectional cavopulmonary anastomosis. Postoperative right atrial pressures were low (average 13 mm Hg), as was the incidence of prolonged pleural effusions (13%). At short-term (average 13 months) follow-up, 77% of patients have had closure of the fenestration, and 92% are in New York Heart Association Class I. We conclude that baffle fenestration with subsequent transcatheter closure results in decreased mortality and morbidity among high risk patients undergoing a Fontan repair, and that the high functional level at short-term follow-up justifies continued aggressive management of such patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1383113

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  3 in total

1.  Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation.

Authors:  Ian H Law; Osman Alam; Edward L Bove; Richard G Ohye; David J Bradley; Sunkyung Yu; Macdonald Dick
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-12

2.  Congenital Heart Defects in Adults : A Field Guide for Cardiologists.

Authors:  Anitra Romfh; Francesca Romana Pluchinotta; Prashob Porayette; Anne Marie Valente; Stephen P Sanders
Journal:  J Clin Exp Cardiolog       Date:  2012-06-15

Review 3.  Hypoplastic left heart syndrome - a review of supportive percutaneous treatment.

Authors:  Tomasz Moszura; Sebastian Góreczny; Paweł Dryżek
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-09-11       Impact factor: 1.426

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.